Open Biology · 2013 · 353 citations · 41 references
The vast majority of all agents used to directly kill cancer cells (ionizing radiation, most chemotherapeutic agents and some targeted therapies) work through either directly or indirectly generating reactive oxygen species that block key steps in the cell cycle. As mesenchymal cancers evolve from their epithelial cell progenitors, they almost inevitably possess much-heightened amounts of antioxidants that effectively block otherwise highly effective oxidant therapies. Also key to better understanding is why and how the anti-diabetic drug metformin (the world's most prescribed pharmaceutical product) preferentially kills oxidant-deficient mesenchymal p53 − − cells. A much faster timetable should be adopted towards developing more new drugs effective against p53 − − cancers.
41
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.2K citations · Full text
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Siân Jones, D. Williams Parsons, Jimmy Lin et al. · Science · 2008 · 4K citations · Full text
Engineering, Genetics, Pathology +17
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Maximilian Diehn, Robert W. Cho, Neethan A. Lobo et al. · Nature · 2009 · 2.5K citations · Full text
A model for p53-induced apoptosis
Kornélia Polyák, Yong Xia, Jay L. Zweíer et al. · Nature · 1997 · 2.5K citations
Medicine, Apoptosis, Cell Death +4